Using the hyperinsulinaemic-euglycaemic clamp as the gold-standard for assessment, recent research has shown that insulin resistance (IR) may be causally linked to left ventricular (LV) diastolic and systolic dysfunction in patients with type 2 diabetes mellitus (T2DM).
An elevated ratio between apolipoproteins B to A-1 (apoB/apoA-1) correlates with a higher incidence of aortic stenosis regardless of previous major adverse cardiovascular events, especially in the elderly and in women, a recent study has found.
Treatment with the HMG-CoA reductase inhibitor atorvastatin in critically ill patients with COVID-19 did not significantly reduce the primary composite outcome of venous or arterial thrombosis risk, treatment with extracorporeal membrane oxygenation (ECMO), or mortality vs placebo in the INSPIRATION-S study presented at ACC.21.
Among patients with newly diagnosed type 2 diabetes, the risk of developing cardiovascular disease (CVD) is elevated in the presence of symptoms indicative of diabetic polyneuropathy, as shown in a study.
In patients with acute coronary syndromes, undergoing a more intensive low-density lipoprotein cholesterol (LDL-C)–lowering therapy during the early disease phase leads to a significant decrease in the risk of long-term major adverse cardiac events (MACEs), according to a study. This benefit is more pronounced for patients with higher baseline and larger reduction in LDL-C levels.
In patients who develop chronic graft-versus-host disease (cGVHD) after haematopoietic cell transplantation (HCT), the risk of thromboembolic events (TEE) seems to be affected by disease severity and donor-recipient ABO blood group, a recent study has found.